BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 10743740)

  • 1. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Population screening for colorectal carcinoma by examining feces for occult hemorrhage].
    Musil D
    Vnitr Lek; 1999 Aug; 45(8):496-9. PubMed ID: 11045153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of fecal occult-blood tests for colorectal-cancer screening.
    Allison JE; Tekawa IS; Ransom LJ; Adrain AL
    N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
    Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
    Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
    Slusser SO; Liberski SM; McGarrity TJ
    Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
    Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
    Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.
    Young GP; St John DJ; Winawer SJ; Rozen P;
    Am J Gastroenterol; 2002 Oct; 97(10):2499-507. PubMed ID: 12385430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass screening for colorectal cancer: compliance in Almopea Region.
    Chrissidis T; Saliangas K; Economou A; Nikoloudis N; Andreadis E; Prodromou K; Georgakis K
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s193-5. PubMed ID: 15655620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].
    Takemasa I; Kikkawa N; Yasui M; Nishisho I; Fujitani K; Mishima H; Hasuike Y; Kobayashi K
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1514-8. PubMed ID: 9725042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
    N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiology and screening of colorectal cancer].
    Dancourt V; Faivre J
    Rev Prat; 2004 Jan; 54(2):135-42. PubMed ID: 15086055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of average-risk individuals for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer.
    Winawer SJ; St John J; Bond J; Hardcastle JD; Kronborg O; Flehinger B; Schottenfeld D; Blinov NN
    Bull World Health Organ; 1990; 68(4):505-13. PubMed ID: 2208563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mass screening for colorectal cancer].
    Faivre J; Tazi MA; Launoy G
    Rev Epidemiol Sante Publique; 1996; 44 Suppl 1():S7-14. PubMed ID: 8935859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
    Tong S; Hughes K; Oldenburg B; Del Mar C
    Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.